Inhalable anti-COVID-19 antibody from TFF and Augmenta tamps down viral load in hamsters
Excerpt from the Press Release:
When startup TFF Pharmaceuticals raised $14 million in a series A in 2018, its intention was to deploy its dry-powder drug-delivery technology toward making novel inhalable therapies for asthma, chronic obstructive pulmonary disease and other serious lung diseases. Then COVID-19 hit, and the company saw an opportunity to apply the platform to the emerging virus.
So, the Austin, Texas-based company teamed up with Augmenta Bioworks in Menlo Park, California, to develop an inhalable monoclonal antibody to treat COVID-19. In hamster models, the drug reduced viral load one day after infection with SARS-CoV-2, the virus that causes COVID, the companies reported (PDF) on the journal preprint site bioRxiv. They plan to start human trials next year, they said in a statement.
TFF is developing inhalable drugs based on a “thin freezing film” technology licensed from the University of Texas at Austin. It is focusing on biologics and small molecules that thus far have not been able to be formulated as inhalable drugs, and it has two in phase 1 trials: TFF for invasive pulmonary aspergillosis (IPA) and TFF TAC-LAC, a dry-powder version of tacrolimus, a commonly used immunosuppressive drug in organ transplants.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?